NICE technology appraisal guidance TA875 supports the use of semaglutide 2.4 mg (Wegovy) for adults who meet specific criteria: BMI 35 kg/m with at least one weight-related comorbidity (such as type 2 diabetes, hypertension, or obstructive sleep apnoea) BMI 3034.9 kg/m in certain higher-risk groups For people from certain ethnic backgrounds including South Asian, Chinese, other Asian, Middle Eastern, Black African, and African-Caribbean groups lower BMI thresholds apply (typically approximately 2.5 kg/m lower than standard thresholds), in line with NHS and NICE guidance on ethnicity-related metabolic risk Treatment must be delivered as part of a specialist weight management service providing multidisciplinary support Treatment duration under TA875 is limited to a maximum of 2 years Should retatrutide receive regulatory approval and a positive NICE appraisal, it is likely that similar eligibility criteria would apply, potentially with additional considerations given its more potent mechanism of action
Through regular follow-up appointments, either in-person or virtually, we will closely monitor your progress and make any necessary adjustments to your treatment plan
Manjishtha Capsules The standardized extract of the widely-known Manjishtha herb (Rubia cordifolia) is used for preparing these capsules
J Alzheimers Dis 30(4):943961 Escribano L, Simn AM, Gimeno E, Cuadrado-Tejedor M, Lopez de Maturana R, Garca-Osta A, Ricobaraza A, Prez-Mediavilla A, Del Ro J, Frechilla D (2010) Rosiglitazone rescues memory impairment in Alzheimers transgenic mice: mechanisms involving a reduced amyloid and tau pathology
